Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 650-659

  Macher Goeppinger, Stephan ^a,b   Aulmann, Sebastian ^a   Tagscherer, Katrin E ^b   Wagener, Nina ^a   Haferkamp, Axel ^a   Penzel, Roland ^a   Brauckhoff, Antje ^a   Hohenfellner, Markus ^a   Sykora, Jaromir ^b   Walczak, Henning ^b   Teh, Bin T ^c   Autschbach, Frank ^a   Herpel, Esther ^a,b   Schirmacher, Peter ^a   Roth, Wilfried ^a,b,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME;

EID: 59449095034     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0284     Document Type: Article

References (44)

1. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9.
2. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin lnvest1999;104:155-62.
3. Walczak H, Miller RE, Ariail K, et al.Tumoricidal activity of tumor necrosis factor-related apoptosis-induc-ing ligand in vivo. Nat Med 1999;5:157-63.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J. Thun M. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
5. Matsubara H, Mizutani Y, Hongo F, et al. Gene therapy with TRAIL against renal cell carcinoma. Mol Cancer Ther 2006;5:2165-71.
6. Tian JQ, Wang ZP, Rodriguez R, Fu JS, Lu JZ, Ma BL. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma. Urology 2006;67:1093-8. Epub 2006 Apr 25.
7. Van Oosten RL, Earel JK, Jr., Griffith TS. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther 2006;13:628-32.
8. Zeng Y, Wu XX, Fiscella M, et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apo-ptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006;28:421-30.
9. Greene FL, Page DL, Fleming ID, Fritz A. AJCC Cancer Staging Manual. 6th ed. New York 2002.
10. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
11. Ganten TM, Koschny R, Sykora J, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006;12:2640-6.
12. Webb J. Effect of more than one inhibitor. In: Enzyme and Metabolic Inhibitors. Vol. 1. New York: Academic Press;1963. p. 466-87.
13. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
14. Seki N, Hayakawa Y, Brooks AD, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 2003;63:207-13.
15. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon 7-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70.
16. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005;11:5188-94.
17. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003;9:3397-405.
18. van Geelen CM, Westra JL, deVries EG, et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuv-antly treated stage III colon cancer patients. J Clin Oncol 2006;24:4998-5004.
19. Strater J, Hinz U, Walczak H, et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002;8:3734-40.
20. Kuijlen JM, Mooij J J, Platteel I, et al.TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 2006;78:161-71.
21. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001;276:16484-90.
22. Baader E. Toloczko A, Fuchs U, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 2005;65:7888-95.
23. Franco AV, Zhang XD, Van Berkel E, et al. The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001;166:5337-45.
24. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of theTNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 1997;7:821-30.
25. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001;20:3888-96.
26. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat Cell Biol 2001;3:409-16.
27. Trauzold A, Siegmund D, Schniewind B, et al.TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006;25:7434-9.
28. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol 2006;290:G129-36.
29. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999;59:2747-53.
30. Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 2007;8:554-8.
31. Cohen H, McGovern F. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
32. Kashyap MK, Kumar A, Emelianenko N, et al. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 2005;10:258-94.
33. Macher-Goeppinger S, Aulmann S, Wagener N, et al. Decoy Receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008;10:1049-56.
34. Ramp U, Caliskan E, Mahotka C, et al. Apoptosis induction in renal cell carcinoma by TRAIL and -γ-radi-ation is impaired by deficient caspase-9 cleavage. Br J Cancer 2003;88:1800-7.
35. Griffith TS. Fialkov JM, Scott DL, et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res 2002;62:3093-9.
36. Dejosez M, Ramp U, Mahotka C, et al. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ 2000;7:1127-36.
37. Jin X,Wu XX, Abdel-Muneem Noun MA, Kakehi Y. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by sub-toxic concentrations of doxorubicin. J Urol 2007;177:1894-9.
38. Wu XX, Kakehi Y, Mizutani Y, et al. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003;104:409-17.
39. Asakuma J, Sumitomo M, AsanoT, AsanoT, Haya-kawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitax-el. Cancer Res 2003;63:1365-70.
40. Fulda S, Jeremias I, Debatin KM. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004;23:7611-20.
41. Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41.
42. Brooks AD, Sayers TJ. Reduction of the antiapop-totic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 2005;54:499-505.
43. Mizutani Y, Nakanishi H, Li YN, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 2007;30:919-25.
44. Mizutani Y, Nakanishi H, Yamamoto K, et al. Down-regulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 2005;23:448-54.